Which has stronger earnings and valuation, AXGN or TFX?

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 11.08 -$15.70M -$0.68 N/A Teleflex $1.99B 2.99 -$905.64M -$22.80 N/A

Is AXGN or TFX more profitable?

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -35.88%. Teleflex's return on equity of 13.29% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Teleflex -35.88% 13.29% 6.55%

Does the media refer more to AXGN or TFX?

In the previous week, Teleflex had 7 more articles in the media than AxoGen. MarketBeat recorded 27 mentions for Teleflex and 20 mentions for AxoGen. Teleflex's average media sentiment score of 0.73 beat AxoGen's score of 0.28 indicating that Teleflex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Teleflex 9 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MMED or AXGN?

In the previous week, AxoGen had 19 more articles in the media than MiniMed Group. MarketBeat recorded 20 mentions for AxoGen and 1 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.34 beat AxoGen's score of 0.28 indicating that MiniMed Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, AXGN or LIVN?

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 11.08 -$15.70M -$0.68 N/A LivaNova $1.39B 3.02 -$242.47M $1.95 39.09

Is AXGN or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.36% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% LivaNova 12.82% 16.36% 7.76%

Does the media refer more to AXGN or LIVN?

In the previous week, AxoGen had 4 more articles in the media than LivaNova. MarketBeat recorded 20 mentions for AxoGen and 16 mentions for LivaNova. LivaNova's average media sentiment score of 0.92 beat AxoGen's score of 0.28 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral LivaNova 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ITGR or AXGN?

Integer has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.29 $102.81M $4.01 31.19 AxoGen $225.21M 11.08 -$15.70M -$0.68 N/A

Is ITGR or AXGN more profitable?

Integer has a net margin of 6.97% compared to AxoGen's net margin of -13.36%. Integer's return on equity of 12.79% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% AxoGen -13.36% -8.90% -6.47%

Does the media favor ITGR or AXGN?

In the previous week, Integer had 15 more articles in the media than AxoGen. MarketBeat recorded 35 mentions for Integer and 20 mentions for AxoGen. Integer's average media sentiment score of 0.69 beat AxoGen's score of 0.28 indicating that Integer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 17 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer AXGN or IRTC?

In the previous week, AxoGen had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 20 mentions for AxoGen and 19 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.94 beat AxoGen's score of 0.28 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral iRhythm Technologies 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

AxoGen (AXGN) Competitors

$46.43 +2.08 (+4.69%)

Closing price 04:00 PM Eastern

Extended Trading

$46.22 -0.21 (-0.45%)

As of 04:48 PM Eastern

Compare

AXGN vs. TFX, MMED, LIVN, ITGR, and IRTC

Should you buy AxoGen stock or one of its competitors? MarketBeat compares AxoGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AxoGen include Teleflex (TFX), MiniMed Group (MMED), LivaNova (LIVN), Integer (ITGR), and iRhythm Technologies (IRTC). These companies are all part of the "healthcare equipment" industry.

How does AxoGen compare to Teleflex?

AxoGen (NASDAQ:AXGN) and Teleflex (NYSE:TFX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

AxoGen presently has a consensus target price of $51.00, indicating a potential upside of 9.84%. Teleflex has a consensus target price of $149.80, indicating a potential upside of 11.37%. Given Teleflex's higher possible upside, analysts plainly believe Teleflex is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

AxoGen has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 0.7% of Teleflex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	11.08	-$15.70M	-$0.68	N/A
Teleflex	$1.99B	2.99	-$905.64M	-$22.80	N/A

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -35.88%. Teleflex's return on equity of 13.29% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Teleflex	-35.88%	13.29%	6.55%

In the previous week, Teleflex had 7 more articles in the media than AxoGen. MarketBeat recorded 27 mentions for Teleflex and 20 mentions for AxoGen. Teleflex's average media sentiment score of 0.73 beat AxoGen's score of 0.28 indicating that Teleflex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Teleflex	9 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Teleflex beats AxoGen on 9 of the 17 factors compared between the two stocks.

How does AxoGen compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and AxoGen (NASDAQ:AXGN) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

MiniMed Group presently has a consensus price target of $21.62, suggesting a potential upside of 10.28%. AxoGen has a consensus price target of $51.00, suggesting a potential upside of 9.84%. Given MiniMed Group's stronger consensus rating and higher probable upside, research analysts plainly believe MiniMed Group is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

MiniMed Group has a net margin of 0.00% compared to AxoGen's net margin of -13.36%. MiniMed Group's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
AxoGen	-13.36%	-8.90%	-6.47%

In the previous week, AxoGen had 19 more articles in the media than MiniMed Group. MarketBeat recorded 20 mentions for AxoGen and 1 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.34 beat AxoGen's score of 0.28 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AxoGen has lower revenue, but higher earnings than MiniMed Group. AxoGen is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.77	-$333M	-$0.68	N/A
AxoGen	$225.21M	11.08	-$15.70M	-$0.68	N/A

Summary

MiniMed Group beats AxoGen on 9 of the 14 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

AxoGen (NASDAQ:AXGN) and LivaNova (NASDAQ:LIVN) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

AxoGen presently has a consensus target price of $51.00, indicating a potential upside of 9.84%. LivaNova has a consensus target price of $83.50, indicating a potential upside of 9.55%. Given AxoGen's higher probable upside, equities research analysts clearly believe AxoGen is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, AxoGen had 4 more articles in the media than LivaNova. MarketBeat recorded 20 mentions for AxoGen and 16 mentions for LivaNova. LivaNova's average media sentiment score of 0.92 beat AxoGen's score of 0.28 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
LivaNova	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.36% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
LivaNova	12.82%	16.36%	7.76%

AxoGen has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	11.08	-$15.70M	-$0.68	N/A
LivaNova	$1.39B	3.02	-$242.47M	$1.95	39.09

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

LivaNova beats AxoGen on 9 of the 16 factors compared between the two stocks.

How does AxoGen compare to Integer?

Integer (NYSE:ITGR) and AxoGen (NASDAQ:AXGN) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Integer has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

In the previous week, Integer had 15 more articles in the media than AxoGen. MarketBeat recorded 35 mentions for Integer and 20 mentions for AxoGen. Integer's average media sentiment score of 0.69 beat AxoGen's score of 0.28 indicating that Integer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	17 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Integer has a net margin of 6.97% compared to AxoGen's net margin of -13.36%. Integer's return on equity of 12.79% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
AxoGen	-13.36%	-8.90%	-6.47%

Integer has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.29	$102.81M	$4.01	31.19
AxoGen	$225.21M	11.08	-$15.70M	-$0.68	N/A

Integer presently has a consensus target price of $109.86, suggesting a potential downside of 12.16%. AxoGen has a consensus target price of $51.00, suggesting a potential upside of 9.84%. Given AxoGen's stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.3% of Integer shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Integer beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does AxoGen compare to iRhythm Technologies?

AxoGen (NASDAQ:AXGN) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

AxoGen presently has a consensus price target of $51.00, suggesting a potential upside of 9.84%. iRhythm Technologies has a consensus price target of $179.36, suggesting a potential upside of 40.30%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, AxoGen had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 20 mentions for AxoGen and 19 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.94 beat AxoGen's score of 0.28 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
iRhythm Technologies	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

AxoGen has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	11.08	-$15.70M	-$0.68	N/A
iRhythm Technologies	$747.14M	5.62	-$44.55M	-$0.86	N/A

iRhythm Technologies has a net margin of -3.53% compared to AxoGen's net margin of -13.36%. AxoGen's return on equity of -8.90% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

AxoGen has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

iRhythm Technologies beats AxoGen on 9 of the 17 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.50B	$5.74B	$6.98B	$13.00B
Dividend Yield	N/A	1.78%	2.59%	9.93%
P/E Ratio	-68.28	24.38	270.86	26.05
Price / Sales	11.08	68.27	662.75	111.30
Price / Cash	N/A	32.43	71.89	50.37
Price / Book	9.73	5.69	13.24	6.24
Net Income	-$15.70M	$148.49M	$3.45B	$342.55M
7 Day Performance	10.00%	4.55%	4.62%	4.29%
1 Month Performance	4.17%	-0.09%	-1.59%	-1.06%
1 Year Performance	229.99%	10.01%	77.38%	22.47%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	2.5196 of 5 stars	$46.43 +4.7%	$51.00 +9.8%	+222.5%	$2.50B	$225.21M	N/A	450	Positive News Analyst Revision
TFX Teleflex	3.2022 of 5 stars	$140.16 +0.3%	$148.90 +6.2%	+24.3%	$6.20B	$1.99B	N/A	15,500	Trending News Earnings Report Dividend Announcement Analyst Forecast
MMED MiniMed Group	2.4878 of 5 stars	$19.08 -0.1%	$21.62 +13.3%	N/A	$5.36B	$3.10B	N/A	8,000
LIVN LivaNova	3.169 of 5 stars	$82.66 +0.2%	$81.38 -1.5%	+60.0%	$4.54B	$1.39B	42.35	3,300	Positive News Earnings Report Analyst Forecast
ITGR Integer	2.3917 of 5 stars	$124.52 +0.1%	$109.86 -11.8%	+19.0%	$4.23B	$1.85B	31.05	11,000	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors